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Summary Both the physiological and pathological functions of cardiovascular organs are
closely related to circadian rhythm, an endogenously driven 24-h cycle. Heart rate, blood pres-
sure, and endothelial function show diurnal variations within a day. The onset of cardiovascular
disorders such as acute coronary syndrome, atrial arrhythmia, and subarachinoid hemorrhage
also exhibits diurnal oscillation. Recent progress in studying the functions and molecular mech-
anisms of the biological clock brought forth the idea that intrinsic circadian rhythms are tightly
related to cardiovascular pathology.
The center of the biological clock exists in the suprachiasmatic nucleus in the hypothalamus.
In addition to this central clock, each organ has its own biological clock system, termed the
peripheral clock. Each cardiovascular tissue or cell, including heart and aortic tissue, cardiomy-
ocyte, vascular smooth muscle cell, and vascular endothelial cell also has intrinsic biological
rhythm. Until recently, little was known about the roles of peripheral clocks in cardiovascular
organs. However, studies using genetically engineered mice revealed their contributions dur-
ing the process of disease progression. Loss of synchronization between the internal clock and
external stimuli can induce cardiovascular organ damage. Discrepancy in the phases between
the central and peripheral clocks also seems to contribute to progression of the disorders. Eluci-
dation of the precise roles of biological clocks in cardiovascular organs will provide us with more
profound insights into the relevance of the circadian rhythm in cardiac pathology. Moreover,
identiﬁcation of themodalities with which we canmanipulate the phase of each peripheral clock
will enable us to establish a novel chronotherapeutic approach. This time-of-day based strategy
may innovate a new paradigm in the prevention and treatment of cardiovascular disorders.
© 2011 Japanese College of Car
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Figure 1 The heterodimer of CLOCK and BMAL binds to the
promoters of per and cry genes, and activates their transcrip-
tion. PER proteins are phosphorylated with casein kinase 1
epsilon (CK1) and degraded through the proteasomal path-
way. However, PER proteins accumulate gradually and suppress
CLOCK/BMAL-mediated transcription of per and cry genes. This
negative feedback loop results in a cyclic activation of the
transcriptional machinery of clock genes, and accounts for an
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ntroduction
he onset of cardiovascular disease (CVD) exhibits a diur-
al oscillation. For example, acute coronary syndrome or
trial ﬁbrillation often occurs in the early morning (Table 1).
n addition to disease onset, several cardiac functions also
how circadian variation, including heart rate (HR) and blood
ressure (BP). Recent evidence supports the idea that the
iurnal variation of cardiovascular physiology and pathology
s tightly related to an intrinsic biological rhythm, named
he circadian clock. In this review, we will summarize the
urrent understanding of the molecular mechanisms of bio-
ogical clocks and their roles in cardiovascular pathology.
olecular clock in mammalian cells
he molecular mechanisms of the biological clock have
een extensively studied [1]. The positive and negative
rms of transcriptional modulators comprise a negative
eedback loop, resulting in a cyclic activation of the tran-
criptional machinery of clock genes (Fig. 1). Positive arms
onsist of transcription activators, CLOCK and NPAS2 and
wo BMAL (BMAL1, BMAL2) proteins, and negative arms
nvolve three period proteins (PER1, PER2, and PER3) and
wo cryptochrome proteins (CRY1 and CRY2). Most of these
lock-related transcription factors are members of the basic
elix-loop-helix (bHLH)/per-arnt-sim (PAS) domain tran-
cription factor family. The heterodimer of CLOCK and
MAL1 binds to the promoters of per and cry genes, result-
ng in the activation of their transcription. PER proteins
re phosphorylated with casein kinase 1 epsilon (CK1) and
egraded through the proteasomal pathway. However, they
ccumulate gradually, form a complex with CRY proteins,
nd suppress CLOCK/BMAL-mediated transcription of per
nd cry genes. This negative feedback loop accounts for an
pproximate 24-h cycle of biological rhythm.
The principal feedback loop consists of CLOCK, BMAL,
ER, and CRY, and is termed the core feedback loop. Other
Table 1 Common onset time of cardiovascular events.
Diseases Onset time
Acute myocardial infarction Early morning
Cerebral infarction Morning
Subarachinoidal hemorrhage Daytime
Atrial ﬁbrillation Morning/night
Ventricular tachycardia/ﬁbrillation Morning
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egative feedback loops help to increase the robustness of
his system. These include the bHLH domain containing the
ranscription factors, deleted in esophageal cancer (dec1
nd dec2), and the nuclear receptor Rev-erb. Besides per
nd cry, the heterodimer of CLOCK/BMAL1 induces circa-
ian expression of its target genes, called clock controlled
enes (CCGs). Arginine vasopressin is one of the CCGs, and
ediates the circadian variation of physiological and patho-
hysiological functions. CCGs also include three proline- and
cid-rich (PAR) basic leucine zipper (bZip) transcription fac-
ors, D-element binding proteins (Dbp), hepatic leukemia
actor (Hlf), and thyrotrophic embryonic factor (Tef) [2],
hich modulate the circadian expression of downstream
CGs. These functions are antagonized by another bHLH
ranscription factor, E4bp4 which is regulated by Rev-erb.
Recently, anucleate red blood cells (RBCs) were demon-
trated to have an intrinsic circadian oscillation system [3].
BCs must have used a different system other than the
ranscription-translation mediated core feedback loop in
ucleated cells, since they lack a nucleus. Further studies
re required to fully understand the molecular interactions
etween clock systems in anucleated cells and those in
ucleated cells.
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Figure 2 The center of the biological clock exists in the
suprachiasmatic nucleus (SCN) in the hypothalamus. Each
peripheral organ also has its own peripheral clock. The central
clock regulates the body’s diurnal function directly by regulat-
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[ing clock controlled gene expression. SCN also affects the phase
of the peripheral clock in each organ, thus indirectly regulating
the physiological functions.
The center of the biological clock, the central clock
is located in the suprachiasmatic nucleus (SCN) in the
hypothalamus [1]. The central clock is essentially involved
in adjusting circadian variations in physiological function by
regulating the autonomic nervous system, humoral media-
tors, or unknown factors. In addition to the central clock in
the SCN, each peripheral organ or cell also possesses circa-
dian expression of core clock genes, which are thus called as
peripheral clocks. The molecular mechanisms of peripheral
clocks are believed to be the same as those of the cen-
tral clock [4]. The central clock regulates the body’s diurnal
function directly by regulating CCG expression, or indirectly
through adjusting the phase of the peripheral clock in each
organ (Fig. 2). It is, however, not fully elucidated how the
central clock adjusts the phases of peripheral clocks.
The factors that can reset and affect the phase of the
internal clock are called zeitgebers (timekeepers). Light is
known as the main zeitgeber for the central clock. In con-
trast, the zeitgebers, however, for peripheral clocks are not
fully elucidated yet. Discovery of the appropriate zeitgeber
for each organ is required to establish a novel therapeu-
tic approach considering time-of-day treatment, namely
chronotherapy.
Peripheral clocks in cardiovascular organs
Peripheral clocks exist in cardiovascular tissues as in other
organs [5]. We conﬁrmed the rhythmic expression of clock
genes in the heart, aorta, and kidney [6,7]. According to
microarray analysis, 8—10% of the genes exhibit circadian
expression in the heart and liver; however, most of them
are speciﬁc to the organ [8]. This result promotes the idea
that the peripheral clock in each organ has a tissue- or cell-
type speciﬁc function. Therefore, it is essential to elucidate
the organ-speciﬁc function of peripheral clocks in order to
fully understand the relevance of circadian rhythm in CVD.
We and other groups have reported the existence of cir-
cadian expression of clock genes in vascular cells including
v
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ascular endothelial cells and vascular smooth muscle cells
VSMCs) [7,9,10]. We searched the CCGs speciﬁc to vascu-
ar endothelial cells, and identiﬁed a membrane protein,
hrombomodulin as regulated by clock genes. VSMCs also
ossess an intrinsic clock rhythm, and angiotensin II can
unction as a zeitgeber in VSMCs. Tissue inhibitors of met-
lloproteinases 1 and 3, collagen 3a1, transgelin1 (sm22)
nd calponin1 were also identiﬁed as CCGs in VSMCs. Vas-
ular function also exhibits diurnal variation. For example,
uman ﬂow-mediated dilation responses are lowest in the
orning [11]. Recent studies using genetically engineered
ice have tested the roles of the internal clock in car-
iovascular disorders. Mice with a mutation in the clock
ene, Per2, produce less nitric oxide, resulting in impaired
ndothelium-dependent vasodilatory responses [12].
Cardiomyocytes also have intrinsic clock systems [13].
orepinephrine, one of the sympathetic neurotransmitters,
unctions as a zeitgeber in cardiomyocytes, and induces
he circadian expression of pyruvate dehydrogenase kinase
sozyme or uncoupling protein-3. In addition, the transcripts
f glucose transporters 1 and 4, muscle-speciﬁc glycogen
ynthase and atrial natriuretic peptide (ANP) were shown
o have circadian expression in cardiomyocytes [14]. The
ircadian expressions of the potassium channels, Kv1.5 and
v4.2 may be associated with the circadian onset of atrial
rrhythmia [15]. Young and co-workers generated a mouse
odel in which the clock system is altered speciﬁcally in
ardiomyocytes, which were designated as cardiomyocyte-
peciﬁed clock mutant mice [16]. Using these mice, they
evealed that several gene expressions related to fatty acid,
riglyceride, and glycogen metabolism are regulated by the
ardiomyocyte clock system in vivo. Most of these ﬁndings
ere obtained from experiments using rodents; however,
ircadian expression of clock genes was conﬁrmed in human
earts as well [17].
iurnal variation and chronotherapy in blood
ressure/hypertension
t is well known that there is a 24-h variation in BP with a
eak in the morning. This variation in BP within a day is con-
idered as representative of both intrinsic and exogenous
actors. Intrinsic factors include autonomic nervous activ-
ty and humoral factors such as cortisol, renin, aldosterone,
asoactive intestinal peptide, and ANP [18]. Of course exo-
eneous factors such as physical activity, emotional state,
eals and the sleep/awake states also affect BP variations.
In healthy individuals, asleep BP is lower than awake
P. We calculate the sleep-time relative BP decline (diur-
al/nocturnal BP ratio) as the following:
awake BP mean − asleep BP mean
awake BP mean
]
× 100
In normal subjects, the ratio is 10—20%, and these indi-
iduals are termed normal dippers. Persons with less than
0% of this score are called non-dippers. Some subjects can
e classiﬁed as extreme-dippers (score >20%), and inverse-
ippers or risers (score <0%) indicating that the asleep BP is
igher than the awake BP (Table 2).
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Table 2 Index of diurnal blood pressure (BP) decline.
An index of BP dipping Diurnal/nocturnal BP ratio*
Normal dipper 10—20%
Non-dipper <10%
Extreme-dipper >20%
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awakening, and 1072 had been randomized to ingest ≥1Inverse-dipper, riser <0%
* [(Awake BP mean− asleep BP mean)/awake BP mean]× 100.
The precise mechanisms of diurnal BP variation have not
een elucidated yet. However, studies in rodents suggest
he involvement of the intrinsic clock in BP rhythm. An SCN
esion in a rat abolished the diurnal variation in BP and
R leaving the diurnal locomotor activity intact [19]. Dele-
ion of Bmal1 in mice abrogated the circadian rhythm of BP
ogether with hypotension because of reduced production
f catecholamines [20]. Peroxisome proliferator-activated
eceptor gamma (PPAR) seems to be involved in this diur-
al BP rhythm, since PPAR exhibits circadian expression in
he aorta, and PPAR binds to Bmal1 promoter and trans-
ctivates it. Deletion of PPAR in vascular endothelial cells
r smooth muscle cells attenuated BP variation within a day
21].
Aldosterone, a hormone that increases the reabsorption
f sodium ions and water, and decreases the uptake of
otassium ions in the kidney, probably plays an important
ole in eliciting BP rhythm. The plasma level of aldos-
erone exhibits a circadian rhythm with a peak during the
leep period; however, Cry1/2-null mice were shown to
roduce a high level of aldosterone constitutively. One of
he aldosterone-producing enzymes, type VI 3-hydroxyl-
teroid dehydrogenase (Hsd3b6) has been shown to have
ircadian expression in normal subjects. However, the
xpression of Hsd3b6 is constitutively high in Cry1/2-null
ice resulting in a salt-sensitive hypertension [22]. Aldos-
erone also regulates one of the BP controlling enzymes,
lpha-subunit of the epithelial sodium channel expression
n the kidney, which may be mediated by regulating Per1
xpression levels [23].
We must emphasize that most of the results on the roles
f the circadian clock in BP variation were obtained from
odent studies, not studies of humans. It is still under debate
hether the variation in BP in humans is regulated by an
ntrinsic circadian clock. In people kept under a condition
f constant light condition for 26 h, a signiﬁcant circadian
hythm in HR but not BP was shown [24]. In contrast, results
f a recent study of humans demonstrated the contribu-
ions of the circadian clock during diurnal BP variations [25].
esynchrony induced by living in a cycle comprised of 28-h
ntervals also elicited hypertension [26]. The major limita-
ion to study the role of circadian clock in human disease
ad been difﬁculty to measure the time of human clock.
owever, a novel and convenient method to detect human
lock rhythm was innovated recently. Akashi et al. using hair
ollicle cells found that the phase of clock gene expression
n these cells accurately reﬂected the individual behavioral
hythms [27]. Further human studies using this method will
elp us to explore the biology of the human circadian clock.
Loss of adequate BP decline during the sleep period may
e a signiﬁcant risk factor for cardiovascular organ damage.
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ypertensive patients with the non-dipper BP pattern are
ound to be more susceptible to heart and kidney damage
28]. Patients with non-dipper BP proﬁle have higher risk
han dipper patients for left ventricular hypertrophy, heart
ailure, myocardial infarction, strokes, kidney albuminuria,
nd progression to end-stage renal disease [29]. Non-dipper
ormotensive patients had almost the same relative hazard
atio of cardiovascular mortality (2.16) as dipper hyperten-
ive patients (2.37) [30]. Inverse-dipper, or riser patients
lso had signiﬁcantly higher incidence of strokes compared
ith those with other patterns of BP variation, suggesting
hat patients with this BP proﬁle may have the highest risk
or cardiovascular events [31].
Considering the heterogeneity of BP proﬁles, it is not
ppropriate to treat all of the hypertensive patients with the
ame regimen. More than 80% of hypertensive patients are
ow taking all of the anti-hypertensive medications in the
orning. Therefore, it is now becoming a physician’s respon-
ibility to treat the patients according to their BP proﬁles
ithin a day.
Chronotherapy aims to provide treatment with maxi-
um beneﬁcial effects, but with minimum adverse effects
y taking into account the intrinsic circadian rhythm of
isease processes or symptoms. Chronotherapy with anti-
ypertensive medication can be most successfully achieved
y adjusting the time of medication within a day. Most of the
nti-hypertensive drugs, such as calcium channel blockers
CCBs), -adrenoceptor antagonists, angiotensin-converting
nzyme (ACE) inhibitors, and angiotensin II receptor block-
rs (ARBs), could exert signiﬁcant effects on the day/night
P ratio [32]. Among the parameters, lower BP during the
leep period, or a decline in sleep BP compared with awake
P appears to be a potent predictor of cardiovascular events
33]. To establish a chronotherapy for hypertensive patients,
t is necessary to identify the BP parameters that can pre-
ict cardiovascular outcomes, and which then can become
herapeutic targets.
The potential beneﬁts of therapeutic normalization of
ircadian BP proﬁles (from non-dippers to dippers) remain
matter of debate. Most studies with chronotherapeutic
pproaches did not differentiate the impact of time-
djusted administration from that of more effective BP
ontrol. Therefore these studies could not provide direct
vidence of whether chronotherapy could prevent cardio-
ascular events more effectively than the conventional
orning administration of drugs.
Very recently, a landmark study was performed to
xamine the direct effect of time-adjusted dosing of
nti-hypertensive drugs on cardiovascular events. The
mbulatory Blood Pressure Monitoring for Prediction of Car-
iovascular Events (MAPEC) study was designed to examine
rospectively whether bedtime medication of ≥1 anti-
ypertensive drugs would result in more normalized BP
roﬁles and greater CVD risk reduction than conventional
herapy whereby all medications are taken upon-waking
34]. Among the 2156 patients who completed this study,
084 had been randomized to ingest all medications uponedications at bedtime. Ingesting medication at bedtime
owered mean sleep-time BP, increased both decline in
leep-time BP, and the numbers of patients with a dip-
ing pattern. More importantly, in those taking medication
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Acute coronary syndrome
BP
HR
Vascular tone
Coagulability
Fibrinolysis
Coronary ﬂow
Early morning
Figure 3 In the early morning, the oxygen demand increases
due to the rises of blood pressure (BP) and heart rate (HR).
In contrast, coronary blood ﬂow decreases, resulting in the
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at bedtime, the relative risk of total CVD events was sig-
niﬁcantly lower than in those taking all medications upon
awakening (0.39 [0.29—0.51], p < 0.001). Interestingly, both
a decrease in sleep BP and an increase of the sleep-
time relative BP decline towards a normal dipping pattern,
were demonstrated as the most signiﬁcant predictors of
event-free survival. These results suggest that those two
parameters can be useful as novel therapeutic targets in
establishing chronotherapy.
Circadian rhythm in acute coronary syndrome
The onset of acute myocardial infarction (AMI) or pulmonary
embolism demonstrates a clear circadian variation with a
peak in the early morning [35]. A number of cardiac func-
tions related to the pathogenesis of myocardial infarction
are known to have circadian variation. Even the shift to day-
light saving time in the spring (so-called summer time) could
inﬂuence the onset of AMI. During the ﬁrst 3 weeks after the
transition, the incidence of AMI was signiﬁcantly increased
[36].
The diurnal variation in the autonomic nervous activ-
ity could account for the circadian onset of AMI. In the
early morning, systolic BP and HR increase, resulting in an
increase in the oxygen demand by the heart. On the other
hand, the vascular tone of the coronary artery rises, and
coronary blood ﬂow decreases in themorning. This mismatch
of oxygen demand and supply in the morning seems to elicit
circadian onset of AMI. Interestingly, circadian onset of AMI
was not shown in patients receiving -blockers, or diabetic
patients with autonomic nervous dysfunction, suggesting the
roles of autonomic nervous system on this diurnal varia-
tion [37]. In addition, hypercoagulability in the morning may
also underlie the circadian onset of AMI. Circulating platelet
numbers and platelet activity may ﬂuctuate in a circadian
fashion [38]. Platelets are activated by catecholamines, so
the rhythmic activation of the autonomic nervous system
can induce oscillations in platelet activity.
The coagulation activity also has a circadian variation.
The plasma concentration of factor VII, the elevation of
which is known as a risk factor for coronary artery disease,
exhibits a diurnal oscillation [39]. Other coagulation-related
factors, such as ﬁbrinogen, prothrombin, factor VIII, and tis-
sue factor pathway inhibitor also exert circadian activation
[40].
The coagulation process can be counterbalanced by
activation of the ﬁbrinolytic pathway, which attenuates
the coagulation processes and prevents thrombosis forma-
tion. The ﬁbrinolytic function, however, decreases in the
morning. Tissue plasminogen activator inhitibor-1 (PAI-1)
regulates the activity of tissue-plasminogen activator (t-PA),
thus strongly inﬂuences ﬁbrinolytic activity. The concen-
tration and activity of PAI-1 were noted to oscillate in a
circadian pattern with a peak in the morning, resulting
in the lower t-PA activity during the morning. Therefore,
the efﬁcacy of tPA therapy to restore the patency of
occluded vessels in AMI patients is time-dependent [41].
As such, the circadian variation of PAI-1 activity seems to
be strongly related to the morning decrease in ﬁbrinolytic
activity. These mismatches of two important pathways, oxy-
gen demand/supply, and coagulation/ﬁbrinolysis underlie
t
d
1
o
tmbalance between oxygen demand/supply. In addition, the
ismatch between coagulation/ﬁbrinolysis augments the morn-
ng onset of acute coronary syndrome.
he morning onset of acute coronary syndrome (Fig. 3).
The tolerance of cardiomyocytes to ischemic injury may
ary depending on the time of day. A recent study inves-
igated whether time of day affects the extent of cardiac
amage induced by ischemic interventions in mice [42].
hey performed ischemia/reperfusion (I/R) at different
imes, which were the sleep-to-wake transition [zeitge-
er time (ZT) 12] and the wake-to-sleep transition (ZT 0).
nterestingly, the hearts in which I/R was performed during
T12 developed a larger infarct area, more severe ﬁbrosis
nd adverse remodeling compared with those with I/R per-
ormed at ZT 0. This time-of-day dependent variation was
bolished in cardiomyocyte-speciﬁc circadian clock mutant
ice, suggesting that this ﬂuctuation is mediated by the
lock system within cardiomyocytes.
The next mechanistic question is how the intrinsic clock
hythm affects circadian PAI-1 activation. We previously
howed that PAI-1 mRNA and protein levels exhibit clear cir-
adian oscillation in the mice heart, aorta, and kidney with
peak in the evening [43]. Rodents are nocturnal, whereas
umans are diurnal, therefore this circadian PAI-1 expres-
ion may account for the morning hypoﬁbrinolytic activity
n human subjects. We also elucidated that the heterodimer
f clock genes, CLIF/BMAL2 and CLOCK, activates PAI-1 pro-
oter activity by binding the E-box elements upstream of
ts promoter [6].
More extensive studies have been performed to eluci-
ate the roles of the circadian clock in the coagulation
athway. Using a mouse model of thrombotic vascular occlu-
ion induced by photochemical injury, a diurnal variation
f thrombogenicity was observed in vivo [44]. Interest-
ngly, endothelial cell speciﬁc ablation of the clock system
BMAL1fx/fxCreTek) attenuated the circadian oscillation of
hrombogenic events. This endothelium-speciﬁc ablation
id not affect systemic ﬁbrinolytic activity such as PAI-
activation, suggesting the PAI-1 independent function
f the endothelial clock system on thrombosis forma-
ion. Thereafter, we further examined the roles of clock
2 N. Takeda, K. Maemura
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Figure 4 Synchronization between the internal clock and
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enes in vascular endothelial cells. We have identiﬁed one
f the membrane proteins in vascular endothelial cells,
hrombomodulin, which had a circadian expression [10].
hrombomodulin inhibits the functions of thrombin or acti-
ating protein C, and exerts an anti-thrombotic effect.
hese results suggest that thrombomodulin protects the
ndothelium from the hypercoaguability that is induced
y PAI-1 in a circadian fashion. However, further study is
equired to understand the biological meaning of circadian
hrombomodulin expression in cardiovascular disorders.
oss of synchronization between central and
eripheral clocks and disease progression
otating-shift workers have a higher risk of cardiac events.
prospective study examining the association between shift
ork and the adverse cardiac events in Japanese male work-
rs revealed that the rotating-shift workers had 2.32-times
igher risk of death from ischemic heart diseases compared
ith a day-time or a ﬁxed-night worker [45].
How does the cardiovascular system beneﬁt through use
f the circadian system? We can easily comprehend the
dea that peripheral clocks are useful for anticipating and
reparing for external stimuli that will occur in the near
uture, such as a BP increase in the morning. For example,
ouse cardiomyocytes exhibit circadian expression of the
ardioprotective agent, Anp. This circadian variation in Anp
xpression seems to protect mouse cardiomyocytes from the
cute BP rise in the evening. Accordingly, most people esti-
ate that loss of synchronization between the internal and
xternal clocks may exacerbate the progression of CVD.
To test this hypothesis, we have to answer the following
wo questions. Are the internal clock systems impaired in
VD? If so, does impairment of the internal clock system
ontribute to the progression of cardiovascular disorders?
Much evidence exists showing alterations in the periph-
ral clock system in CVD. For example, rat heart with
ypertrophy lost rhythmic expression of PAR transcription
actors (Dbp, Hlf) and Anp [14]. The oscillation of clock
ene expression was attenuated after I/R of the mouse heart
n the ischemic region, whereas it was not affected in the
on-ischemic region [46]. Hypertension, diabetes, and aging
lso affect the internal circadian rhythm, suggesting that the
nternal clock system is disorganized in CVD.
Phase shift of the light/dark (L/D) cycle disrupted the
hythmicity of cardiomyopathic hamsters and shortened
ongevity [47]. A series of elegant studies performed by
artino et al. provided us with profound insights. They
erformed studies of mice with pressure overload car-
iac hypertrophy stress (transverse aortic constriction),
eeping them under either a rhythm-disruptive 20-h (L/D
0/10) or normal 24-h (L/D 12/12) cycle [48]. The rhythm-
isrupted mice exhibited lower cardiac function (increased
eft ventricular dimensions and reduced contractility) with
ncreases in perivascular and interstitial ﬁbrosis compared
ith normal-rhythmmice. Interestingly, this decrease in car-
iac function was reversed when the rhythm was converted
o normal cycle. They also used mutant hamsters, termed
/tau which had a 22-h rather than a 24-h circadian cycle.
hey noticed that these mutant mice developed cardiomy-
pathy with severe ﬁbrosis and impaired cardiac function
s
t
i
f
oxternal stimuli is probably critical in maintaining normal health
nd homeostasis. In contrast, a desynchrony between them elic-
ts the progression of organ damage.
hen kept under the normal 24-h cycle. Interestingly, this
ardiac pathology was reversed when the mice were kept
nder a 22-h cycle, the length of their intrinsic rhythm. SCN
blation, a procedure to eliminate the endogenous clock
ystem, also reversed the cardiac pathology. These results
ndicated that it was not the disruption of the peripheral
lock system that induces the progression of cardiovascu-
ar disorders, but a desynchrony between the internal and
xternal clock that elicits the progression of CVD (Fig. 4).
robably desynchrony between central and peripheral clocks
lso exacerbates disease progression.
These results suggest that the normal circadian orga-
ization is critical for maintaining homeostasis, and that
isturbance of the rhythm can induce the progression of
rgan damage. Therefore, the dysregulation of circadian
hythm can induce the development of cardiac diseases.
oreover, reversal of the deregulated circadian rhythm or
esynchronization of each clock may become a promising
herapeutic target to prevent disease progression. Further
tudies are needed to identify a modality that can manip-
late the phase of each peripheral clock, which is termed
eitgeber (time-keeper). Thiazolidinedione, an agonist for
PAR, might be a potential candidate for this purpose.
PAR indeed induces Bmal1 expression in cardiovascular
rgans [21]. Another nuclear receptor, PPAR, can be a
otential target as well. PPAR plays an important role in
ood-induced entrainment in mouse heart [49]. Fenoﬁbrate,
PPAR ligand, prominently reduced nocturnal BP in human
atients [50].
onclusion
he peripheral clock system within each cardiovascular
rgan seems to play signiﬁcant roles during the progres-
ion of cardiovascular disorders. Synchronization between
he internal clock and external stimuli is probably critical
n maintaining normal health and homeostasis. In addition,
ailure to harmonize the phase of the central clock with that
f the peripheral clock may exacerbate disease progression.
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Understanding the precise functions of these biological
clocks, and the identiﬁcation of the modalities to manipu-
late those systems will enable us to establish a novel type
of therapeutic strategy, named chronotherapy. Further stud-
ies are warranted to fully elucidate this orchestration of
biological systems.
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